DekaBank Deutsche Girozentrale Decreases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

DekaBank Deutsche Girozentrale cut its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 6.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 171,376 shares of the biopharmaceutical company's stock after selling 12,000 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.14% of Catalyst Pharmaceuticals worth $4,154,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $27,000. Charles Schwab Investment Management Inc. increased its position in shares of Catalyst Pharmaceuticals by 6.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company's stock worth $26,023,000 after purchasing an additional 79,182 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Catalyst Pharmaceuticals by 1.6% during the 4th quarter. Victory Capital Management Inc. now owns 296,080 shares of the biopharmaceutical company's stock worth $6,179,000 after purchasing an additional 4,575 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $339,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $6,887,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Stock Down 0.2%

NASDAQ CPRX traded down $0.04 during trading on Friday, hitting $21.81. The stock had a trading volume of 1,402,938 shares, compared to its average volume of 1,134,850. The company has a market capitalization of $2.66 billion, a PE ratio of 13.89, a PEG ratio of 0.89 and a beta of 0.66. The firm has a 50 day moving average price of $23.45 and a 200 day moving average price of $22.89. Catalyst Pharmaceuticals, Inc. has a twelve month low of $15.34 and a twelve month high of $26.58.

Analyst Ratings Changes

Separately, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Six equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $32.83.

Insider Activity

In other news, insider Gary Ingenito sold 200,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the transaction, the insider owned 68,873 shares in the company, valued at approximately $1,630,912.64. This trade represents a 74.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Preethi Sundaram sold 2,324 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total value of $61,376.84. Following the completion of the transaction, the insider owned 42,681 shares of the company's stock, valued at $1,127,205.21. The trade was a 5.16% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 247,924 shares of company stock valued at $5,879,369. 10.40% of the stock is currently owned by corporate insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.